Retinoic Acid Receptor Alpha (RARα; NR1B1)

(From RefSeq)

This gene represents a nuclear retinoic acid receptor. The encoded protein, retinoic acid receptor alpha, regulates transcription in a ligand-dependent manner. This gene has been implicated in regulation of development, differentiation, apoptosis, granulopoeisis, and transcription of clock genes. Translocations between this locus and several other loci have been associated with acute promyelocytic leukemia. Alternatively spliced transcript variants have been found for this locus

NRR Pathway

RAR gene expression

 

Retinoic Acid Receptor Alpha Structure

(From Structure)

Link

(From Aceview)

There are 217 articles specifically referring to this gene in PubMed. Functionally, the gene has been tested for association to diseases (Alcoholism; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Bipolar Disorder; Breast Neoplasms; Carcinoma; Cell Transformation, Neoplastic; Cholesterol, HDL/blood*; Chromosome Aberrations; Chromosome Disorders and 11 others), proposed to participate in pathways (Acute myeloid leukemia, Degradation of the RAR and RXR by the proteasome, Map Kinase Inactivation of SMRT Corepressor, Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells, Pathways in cancer, Regulation of transcriptional activity by PML, Transcription Regulation by Methyltransferase of CARM1) and processes (cellular response to estrogen stimulus, negative regulation of gene-specific transcription, positive regulation of binding, positive regulation of cell cycle, positive regulation of cell proliferation, positive regulation of gene-specific transcription, positive regulation of transcription from RNA polymerase II promoter, regulation of transcription, DNA-dependent). Proteins are expected to have molecular functions (metal ion binding, protein domain specific binding, steroid hormone receptor activity, transcription coactivator activity and 2 others) and to localize in nucleus. Putative protein interactors have been described (ANP32A, ARNTL, BAG1, BTG1, CCND3, CDK7, CLOCK, CNOT1, COPS2, ESR1 and 58 others). 

(From HuGENavigator)

  • Cleft Lip  
  • Cleft Palate  
  • Cardiovascular Diseases  
  • Edema  
  • Metabolic Syndrome X  
  • Diabetes Mellitus, Type 2  
  • Disease Models, Animal  
  • Drug Toxicity  
  • Assays

    INDIGO Logo 2012
     
  • Diabetes Complications  
  • Alcoholism  
  • Alzheimer Disease  
  • Attention Deficit Disorder with Hyperactivity  
  • Autistic Disorder  
  • Bipolar Disorder  
  • Myopia  
  • Neoplasms  
  • Neural Tube Defects  
  • Obesity  
  • Osteoporosis  
  • Schizophrenia  
  • Hypercholesterolemia  
  • Leukemia, Myeloid, Acute  
  • Liver Cirrhosis  
  • Meningomyelocele  
  • Mental Disorders  
  • Fatty Liver  

Assay Kits and Services are available from INDIGO Biosciences.

Kits are offered in different assay formats to accommodate researchers’ needs: 3x 32, 1x 96, and 1x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications. Assay systems are all inclusive, providing reporter cells, optimized growth media, media for diluting test compounds, a positive-control agonist, luciferase detection reagent, a white assay plate, a detailed protocol, and a protocol quick guide. All kits are shipped on dry ice.

RARα Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.

The principle application of this assay product is in the screening of test samples to quantify functional activities, either agonist or antagonist, that they may exert against the human retinoic acid receptor. This kit product is an all-inclusive assay system that includes, in addition to RARα Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.

NR1B1; RAR

(From Aceview)

The gene contains 22 distinct gt-ag introns. Transcription produces 17 different mRNAs, 14 alternatively spliced variants and 3 unspliced forms. There are 7 probable alternative promotors, 3 non overlapping alternative last exons and 7 validated alternative polyadenylation sites (see the diagram). The mRNAs appear to differ by truncation of the 5′ end, truncation of the 3′ end, presence or absence of 7 cassette exons, overlapping exons with different boundaries, splicing versus retention of one intron. 1103 bp of this gene are antisense to spliced gene sneyvybu, raising the possibility of regulated alternate expression. Efficacy of translation may be reduced by the presence of a shorter translated product (uORF) initiating at an AUG upstream of the main open reading frame (in variant bAug10, cAug10, eAug10, gAug10, hAug10, iAug10). 

Gene RARA

(From STRINGS)

NCOR2, RXRA, PML, NCOR1, Rxr, NCOA3, NCOA1, NRIP1, ZBTB16, RARB, NCOA2, KAT2B, TRIM24, RXRB, RARA

(From KEGG)

  • 13-cis-retinoic acid
  • 9-cis-retinoic acid
  • acitretin
  • adapalene
  • arsenic trioxide
  • etretinate
  • tazarotene
  • tretinoin

(From BioGPS)

203749_s_at_med